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It is well established that diabetes can be detrimental to bone health, and its chronic complications have been associated with an
increased risk of osteoporotic fracture. However, there is growing evidence that the skeleton plays a key role in a whole-
organism approach to physiology. The hypothesis that bone may be involved in the regulation of physiological functions, such
as insulin sensitivity and energy metabolism, has been suggested. Given the roles of insulin, adipokines, and osteocalcin in these
pathways, the need for a more integrative conceptual approach to physiology is emphasized. Recent findings suggest that bone
plays an important role in regulating intermediary metabolism, being possibly both a target of diabetic complications and a
potential pathophysiologic factor in the disease itself. Understanding the relationships between bone turnover and glucose
metabolism is important in order to develop treatments that might reestablish energy metabolism and bone health. This review
describes new insights relating bone turnover and energy metabolism that have been reported in the literature.
1. Introduction
Osteoporosis is a skeletal disorder characterized by compro-
mised bone strength which clinical and public health impor-
tance is due to the associated fractures [1–4]. Diabetes
mellitus (DM) is a metabolic disorder characterized by
changes in protein and lipid metabolism, combined with
chronic elevations in serum glucose [5–7]. It is well estab-
lished that type 1 and type 2 DM have an effect on bone den-
sity and metabolism. Osteoporosis and diabetes are prevalent
diseases with significant associated morbidity and mortality.
It is important to understand the mechanisms leading to
diabetes, osteoporosis, and diabetic bone pathology in order
to develop treatments that might reestablish energy metab-
olism and bone health. The relationship between diabetes
and osteoporosis is complex [8–10]. It seems that both type 1
and type 2 diabetes can be detrimental to bone health and its
chronic complications have been associated with an increased
risk of osteoporotic fracture [1–3]. Most biochemical markers
of bone resorption are related to collagen breakdown products
or to various collagen crosslinks and telopeptides [11–13]. At
present, serum C-terminal peptide-bound crosslinks of type I
collagen (CTX-1) have been chosen as the reference standard
for bone resorption rate, whereas osteocalcin is considered a
good marker of bone formation [14–16]. Also, osteocalcin is
a bone-specific protein that acts as a hormone regulating glu-
cose metabolism. Several studies have indicated that hyper-
glycemia induces a low turnover rate by evoking osteoblast
dysfunction and suppressing serum osteocalcin levels. Values
of osteocalcin were associated with glucose levels. These find-
ings suggest that mature osteoblast function is specifically
affected by glucose metabolism in type 2 diabetes (T2DM)
[13, 17–19]. However, skeleton plays a key role in a whole-
organism approach to physiology, such as regulation of bone
mass, energy metabolism, and fertility. Consequently, the
roles of leptin, serotonin, insulin, and osteocalcin in these
pathways have been postulated [5, 20–23]. Incipient sugges-
tions refer that low bone mass is detected in type 1 diabetes
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(T1DM) although the pathogenesis is likely to be multifacto-
rial. Additionally, bone is metabolically active, secreting
growth factors and proteins that modulate insulin sensitivity
and insulin secretion [2, 3, 15]. Furthermore, osteocalcin can
regulate peripheral insulin sensitivity and stimulate insulin
synthesis. These findings take bone beyond its function of
body support and organ protection, performing an impor-
tant role in regulating intermediary metabolism, being possi-
bly both a target of diabetic complications and a potential
pathophysiologic factor in the disease itself [5, 20, 24, 25].
The insights that diabetes affects bone turnover are way
more described in the literature than the inverse perspective,
which we intend to do. The aim of this review is to present an
overview about the possibility of disrupted bone turnover
inducing changes in energy metabolism.
2. Endocrine Nature of Bone
Bone has been viewed as a relatively static tissue, essential for
locomotion, body support, and organ protection, but it is also
a regulator of numerous metabolic processes that are inde-
pendent of mineral metabolism. Bone integrity and its nor-
mal function depend on other organs but may also affect
them. Emerging evidence suggests that bone is metabolically
active and can be considered as a true endocrine organ,
revealing an integrative physiology where bone takes an
important role in regulating intermediary metabolism.
Indeed, bone has been considered an endocrine organ
because of its capacity to secrete osteocalcin, a molecule
expressed by the most osteoblast-specific gene [23, 24, 26–
28]. Epidemiological studies in humans performed to analyze
the relationship between osteocalcin and metabolic parame-
ters, such as glycaemia, insulin secretion, β-cell proliferation,
and lipid profile, have added information on the potential
impact of the skeleton on energy regulation and glucose
metabolism, through osteocalcin [7, 9, 23, 29].
2.1. Osteocalcin Secretion and Bioactivity. Osteocalcin is a
small specific protein synthesized by osteoblasts containing
three glutamic acid residues (13, 17, and 20 Glu in mouse
and 17, 21, and 24 Glu in human) [22, 23, 30] and modified
by carboxylation into gamma-carboxyglutamic acid residues,
generating bone Gla protein (BGP) or osteocalcin. Gla
residues are accountable for osteocalcin high affinity for
hydroxyapatite, the mineral component of bone extracellular
matrix (ECM) [27, 31]. Osteocalcin is detected at high con-
centrations as a component of the ECM [24, 30]. Being phar-
macologically active, osteocalcin also acts as a hormone on
glucose and fat metabolism [15, 24, 27]. After secretion,
osteocalcin is stored in the bone ECM in carboxylated form
(with no metabolic impact) and, to accomplish its beneficial
effects on glucose metabolism, osteocalcin has to be activated.
The osteoclast-mediated bone resorption promotes the low
pH necessary for osteocalcin decarboxylation and activation.
Studies suggest that the activation of osteocalcin depends on
the coordination between bone formation by osteoblasts and
bone resorption by osteoclasts. The acid pH is sufficient to
decarboxylate the first GLA residue of osteocalcin (GLA13)
and this undercarboxylated (GLU13) fragment of osteocalcin
is in fact the active circulating fraction of osteocalcin, acting
as a hormone [20, 21, 32, 33]. Undercarboxylated osteocalcin
increases insulin sensitivity and secretion [27, 34–36], and
serum levels of undercarboxylated osteocalcin negatively cor-
relate with insulin resistance, obesity, and diabetes [7, 17, 37–
39]. Therefore, the undercarboxylated form of osteocalcin
appeared to mediate the metabolic effects of this hormone,
such as increased β-cell proliferation, insulin secretion, insu-
lin sensitivity [5, 16, 31], and adiponectin expression [5, 31,
40]. However, other studies in cell cultures have shown that
both undercarboxylated and carboxylated forms of osteocal-
cin increase basal and insulin-stimulated glucose transport,
whereas the effect of the carboxylated form was less clear
[5, 41]. Lately, it was suggested that insulin signaling in oste-
oblasts is involved in the regulation of the body glucose
homeostasis by stimulating osteocalcin decarboxylation indi-
rectly, through the activation of osteoclasts [16, 24, 27–29].
Osteocalcin bioactivity is affected by insulin signaling in
osteoblasts, increasing bone resorption through osteoproteg-
erin (Opg) downregulation [24, 25, 27]. Opg is a protein, also
known as osteoclastogenesis inhibitory factor. It is a member
of the TNF-receptor (tumor necrosis factor) that acts as an
inhibitor of osteoclast maturation and activation [16, 33].
Thus, osteocalcin carboxylation is regulated by insulin sig-
naling by inhibiting the expression of Opg, that promotes
the activity of osteoclasts, and consequently bone resorption
stimulation [16, 33, 42]. On the other hand, the acid pH of
the resorptive lacunae induces osteocalcin decarboxylation
[20, 24, 43, 44]. As osteocalcin stimulates insulin secretion,
there is a feedback mechanism between osteocalcin and insu-
lin activity and its negative regulators are in place to respond
to these signals [21, 42, 45]. Osteocalcin expression is also
directly controlled downstream of the insulin receptor by
Runx2 (Runt-related transcription factor 2), a key tran-
scription factor associated with osteoblast differentiation
[42, 46, 47].
Osteocalcin, the most abundant noncollagenous bone-
derived specific peptide, may stimulate adipose tissue to
secrete adiponectin, an insulin-sensitizing factor [5, 25, 27,
48]. Leptin secretion by adipocytes fuels the sympathetic ner-
vous system in the brain, signaling osteoblasts to enhance Esp
(embryonic stem cell phosphatase) expression via ATF4
(activating transcription factor 4) [24, 46, 47, 49]. ATF4 is a
member of a transcription factor family and is essential in
many biological mechanisms, such as in the stress response,
medullary hematopoiesis and bone resorption [24, 46, 48,
50]. Esp, a gene expressed in osteoblasts and encoding osteo-
testicular protein tyrosine phosphatase (OST-PTP), is known
to antagonize insulin signaling in osteoblast for osteocalcin
carboxylation [10, 24, 27, 31]. OST-PTP negatively regulates
insulin receptor signaling and decreases osteocalcin activity
by stimulating osteocalcin carboxylation [5, 7, 9, 21]. Since
Esp ablation in mice may induce undercarboxylated osteo-
calcin to rise, improvement of glucose handling, and decreas-
ing fat mass, osteoblasts might be considered as endocrine
cells, controlling energy metabolism. Those animal models
display an increase in β-cell proliferation, insulin secretion,
and sensitivity that protect them from induced obesity and
diabetes [5, 9, 31, 42]. These metabolic advantages are lost
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by the concomitant deletion of one allele of osteocalcin [5, 41,
51, 52]. Conversely, similar to osteocalcin-deficient mice,
mice overexpressing Esp showed decreased levels of under-
carboxylated osteocalcin, developed obesity, and insulin
resistance [10, 31, 45, 53]. In addition, osteoblast-specific
FoxO1 deficiency is associated with an anabolic metabolism
profile due to increased osteocalcin expression and decreased
expression of Esp [9, 21, 52, 53]. The transcriptional factor
FoxO1 is also expressed in osteoblasts. It stimulates osteocal-
cin carboxylation and thus its inactivation, being a major
negative mediator of insulin receptor in β-cells, hepatocytes,
myoblasts, and adipocytes. Particularly, FoxO1 promotes
gluconeogenesis in hepatocytes through specific gluconeo-
genic enzymes [36, 52, 53].
2.2. Testosterone, Glucagon-Like Peptide-1, and Bone.
Recently, osteocalcin has also been found to regulate glucose
homeostasis and male reproductive functions, stimulating
testosterone biosynthesis in Leydig cells, via a pancreas-
bone-testis axis. Testosterone is a sex steroid hormone that
displays testicular functions, such as germ cell survival and
spermatogenesis and other functions beyond reproduction,
among which is the regulation of bone metabolism. Since
endocrine regulation is liable to feedback mechanisms, the
hypothesis that bone may regulate the synthesis and secre-
tion of sex steroid hormones has been raised [54]. Thus, it
has been postulated that bone, energy metabolism, and
reproduction may be interrelated [22, 23]. This functional
coordination may be mediated by osteocalcin receptor
GPRC6A. Osteocalcin binds to Gprc6a expressed in Leydig
cells of the testes, promoting cAMP production that leads
to the expression of several genes encoding the enzymes that
are necessary for testosterone biosynthesis [54, 55]. In
Gprc6a, knockout mice were observed with increased fat
mass, disrupted testosterone production, insulin secretion,
and glucose homeostasis [56]. Insulin signaling in osteoblasts
enhances osteocalcin activity, which, in turn, favors insulin
secretion, contributing to the biosynthesis of testosterone
in an osteocalcin-dependent way. Testosterone, on the
other hand, favors bone growth, maturation, and mainte-
nance [22, 23].
Interestingly, when orally administered, the osteoblast-
derived hormone osteocalcin has the ability to indirectly
regulate insulin secretion, not only through production of
other insulin-regulating hormones, such as testosterone, but
also by stimulation of intestinal GLP-1 secretion [56].
Glucagon-like peptide-1 (GLP-1) has been shown to regulate
both bone remodeling and energy homeostasis [38]. This
incretin hormone is secreted by L cells in the lower small
intestine, in response to food intake. The main role of GLP-
1 is to stimulate insulin secretion by pancreatic β-cells in a
glucose-dependent manner and suppress glucagon secretion
from α-cells. GLP-1R is a G protein-coupled receptor, play-
ing a role in glucose metabolism. GLP-1 binds to its receptor
in order to exert its biological effect, increasing intracellular
cAMP and stimulating ATP production in the mitochondria
and insulin secretion [57, 58].
GLP-1 receptor was found to be expressed in a variety of
tissues such as the stomach, heart, lungs, kidneys, and brain
[57, 59]. In addition to the pancreatic effects, reduction in
body weight, delay in gastric emptying, and appetite suppres-
sion have been reported, suggesting its potential in obesity
treatment. Recent studies revealed that GLP-1 might also
take part in bone metabolism. Nuche-Berenguer et al.
(2009, 2011) discovered that osteoblastic precursor cells
express functional GLP-1 receptors and that the administra-
tion of GLP-1 in both normal and diabetic rats normalizes
impaired bone structure, promotes bone formation, and
restores bone mineral densities, suggesting a possible ana-
bolic effect of GLP-1 on trabecular bone [57, 58].
It seems that GLP-1 action is more extensive than it was
thought, and results reveal the potential role of this incretin
in bone metabolism. T2DM patients are already starting
treatments with GLP-1 mimetics [59]. Additionally, these
discoveries emphasize the potential use of GLP-1/GLP-1R
in diabetes-related bone defects treatments [57].
2.3. Other Bone-Derived Hormones. Fibroblast growth factor-
23 (FGF23) is another peptide hormone that is produced by
bone cells and beyond its role in mineral metabolism also acts
in other tissues, primarily in the kidney [60–62]. The FGF23
is an osteocyte-derived hormone considered the major regu-
lator of circulating phosphate levels and 1,25-dihydroxyvita-
min D metabolism via a bone-kidney axis [63]. Increased
serum concentrations of circulating FGF23 are observed in
many hypophosphatemic disorders and it negatively impacts
in chronic kidney disease, a global health problem [60, 61].
FGF23 enhances phosphate excretion into urine by restrict-
ing its absorption in the proximal renal tubule. Additionally,
this hormone suppresses intestine absorption of Ca and cir-
culating phosphate by lowering phosphate levels and reduc-
ing 1,25-dihydroxyvitamin D synthesis [62, 63]. However,
in a regulatory loop, decreased phosphate and 1,25-dihy-
droxyvitamin D concentrations are great stimulators of
FGF23 synthesis in vivo and in vitro [62], although the spe-
cific mechanisms of phosphate sensing and FGF23 secretion
in osteocytes are yet to be better understood [62, 63].
Additionally, it is important to mention the newly identi-
fied role of bone-derived lipocalin 2 (LCN2) on appetite con-
trol in mice. It was demonstrated by molecular and genetic
analyses in mice that LCN2 is an enriched osteoblast-
derived hormone [64]. This protein was thought to be mostly
produced by adipose tissue; however, it was observed that
LCN2 secretion is tenfold higher in the osteoblasts than in
the white adipose tissue. The authors discovered that LCN2
suppresses the appetite, suggesting a novel role for bone in
metabolic regulations [64]. The investigators concluded that
LCN2 is a new ligand for melanocortin 4 receptor (MC4R)
in the hypothalamus, by crossing the blood-brain barrier
and suppressing the MC4R-dependent anorexigenic (appe-
tite-suppressing) pathway. Although there is further investi-
gation ahead, these findings highlight the potential role of
bone in the regulation of obesity and insulin resistance [64].
3. Adipose Tissue in Control of Bone Mass
Adipose tissue is a metabolically active tissue with endocrine
effects. It produces cytokines and adipokines that may
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influence the activity of other tissues [4, 45, 65, 66]. There are
distinctive types of adipose tissues (subcutaneous white
adipose tissue, visceral white adipose tissue, brown adipose
tissue, and bone marrow adipose tissue) with different rela-
tionships with BMD (bone mineral density) in altered bone
remodeling. However, the contribution of bone marrow
adipose tissue in fat-bone interface is more established. The
amount of bone marrow adipose tissue is correlated to
BMD loss in ageing, menopause, and anorexia nervosa and
is considered a marker of compromised bone integrity [67,
68]. Adipocytes secrete leptin and adiponectin, and these adi-
pokines have recently revealed important involvements in
bone cells and control of energy homeostasis [5, 26, 69, 70].
Bone marrow mesenchymal stem cells give rise to both oste-
oblasts and adipocytes. In ageing process and in many sec-
ondary causes of osteoporosis, the hematopoietic bone
marrow in trabecular bone is followed by progressive mar-
row infiltration with adipocytes and replaced by adipose tis-
sue [20, 31, 53]. The interaction between adipose tissue and
bone is notable and the adipose tissue distribution affects
bone mass. It has been proven that visceral adipose tissue is
a negative predictor of lumbar spine and whole body BMD
in obese girls [71]. Also, high body mass index reduces frac-
ture risk, while low body mass increases bone loss, leading
frequently to osteoporosis [4, 5, 20, 27]. Thus, bone remodel-
ing and energy metabolism are believed to be connected.
3.1. Leptin and Its Actions. The distribution and the excess of
adipose tissue is an important factor in the induction of insu-
lin resistance and the individual predisposition to DM. Both
obesity and lipodystrophy are risk factors for the develop-
ment of insulin resistance and glucose intolerance. Fat is an
important source of peptides and cytokines which modulate
metabolic homoeostasis [4, 69, 70]. Adipocytes affect bone
and energy metabolism by secreting leptin. Leptin may influ-
ence bone metabolism through different pathways via direct
and indirect actions. Leptin may improve insulin sensitivity,
possibly mediated by insulin-like growth factor-binding pro-
tein 2. This fact may have positive effects on bone, proposing
that leptin may directly stimulate osteoblasts function [5, 45,
69, 72]. However, leptin regulates indirectly osteoblasts
through the hypothalamus by stimulating sympathetic tone
and suppressing bone formation, enhancing bone resorption
by decreasing osteoblast proliferation, via skeletal β2 adren-
ergic receptors on osteoblasts [31, 49, 73]. Researchers sug-
gest that the predominant effect of leptin on the regulation
of bone mass is through the central nervous system [46, 74,
75]. The neuronal mediation between leptin signaling in the
brain and in osteoblasts is the SNS, through β2 adrenergic
receptors [20, 49, 73].
Leptin is an adipocyte-specific molecule, crucial in appe-
tite regulation and bone metabolism. Its main function is to
inhibit appetite and increase energy expenditure. It stimu-
lates the sympathetic nervous system (SNS) by acting in the
brain through a single receptor, and it is considered to pro-
vide the brain feedback concerning energy storage [27, 53,
76]. Over the evolution period, leptin only appears in verte-
brates and it is associated with bone remodeling; thus, bone
is considered as a key target for this hormone. Moreover,
researchers proposed that the threshold of leptin signaling
necessary to affect bone mass is lower than that needed to
affect appetite [20, 73, 77, 78]. Observations in rat model
experiments revealed that low doses of leptin prevented bone
loss and high doses inhibited femoral growth and triggered
decreased bone formation and resorption [5, 79].
3.2. Leptin, Serotonin, and Bone. The relationship of leptin to
bone mass has proven to be complex due to the direct and
indirect actions of leptin on bone. Leptin receptor (Lepr) is
vastly expressed in ventromedial (VMH) and arcuate (Arc)
hypothalamic neurons, and injuries in these neurons demon-
strated their role in the bone and appetite regulation [5, 49,
80]. However, a novel approach suggests that leptin receptor
in hypothalamic ventromedial neurons is not necessary for
triggering leptin action [5, 81]. A selective inactivation of
Lepr in VMH or arcuate neurons in mice fed on normal
chow did not affect appetite or the increase of bone mass.
Probably leptin signals other sites of the brain to regulate
metabolism, as the synthesis of neurotransmitters that will
later act in the hypothalamus. Serotoninergic neurons might
mediate this action since leptin deficiency impacts on bone
turnover; thus, metabolism can be overturned by obstructing
serotonin secretion in the brainstem [5, 7, 27, 73]. Neuronal
connections between serotonin-producing neurons and
hypothalamic neurons may exist and possibly have essential
functions, as inactivation of serotonin receptors in specific
neurons of the hypothalamus resulting in osteoporosis or
anorexia. The observation that individuals chronically
treated with serotonin reuptake inhibitors can develop low
bone mass suggested that serotonin and leptin signaling
may intersect in the brain [20, 27, 82, 83]. Serotonin signaling
in VMH neurons reduces the activity of the SNS, inhibiting
the formation of bone mass and serotonin signaling in Arc
neurons inhibiting appetite [20, 73, 84]. Leptin may regulate
energy metabolism through where it signals in the brain.
Serotonin suppresses catecholamine synthesis from hypo-
thalamic neurons (actions that favor increase of bone mass),
and leptin inhibits serotonin for binding serotoninergic neu-
rons of brainstem. As a result, osteoblasts are inhibited for
catecholamine binding to their beta-2 adrenergic receptors
and bone formation and osteocalcin synthesis are compro-
mised [7, 28, 73].
However, beyond acting as a neurotransmitter, serotonin
is also synthesized in the gut, and there are studies suggesting
there is no role of serotonin in the bone tissue through the
brain, but serotonin gut-derived. Peripheral serotonin pro-
duced in the gut contributes to circulating serotonin levels
and is a negative regulator of osteoblast proliferation, bone
mass, and quality [85, 86]. This negative modulation on bone
is thought to be mediated by serotonin receptors and trans-
porter in osteoblasts and osteoclasts. In addition, Cui et al.
suggest that serotonin can bind covalently with proteins, by
transglutaminase-mediated serotonylation reaction, modify-
ing their function [86]. These authors explain that serotonin
has significant interactions with plasma fibronectin, interfer-
ing on bone extracellular matrix assembly and mineraliza-
tion; hence, increased peripheral serotonin concentrations
may weaken bone matrix and negatively affect bone quality
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and mass [86]. Furthermore, Vernejoul et al. showed that
bone might gather a microserotoninergic system by synthe-
tizing serotonin through osteoclasts that can act locally on
osteoclast precursor differentiation [87].
3.3. Adipokines and Diabetes. Neumann et al. observed that
in T1DM patients, leptin seems to be positively related with
daily insulin dose, body mass index, and body fat mass, while
in healthy controls, such association was not observed [45].
However, in these T1DM patients, adiponectin was higher
for both males and females and appears to be inversely
related with body mass index and daily insulin dose. Addi-
tionally, the study showed that, in both T1DM and control
groups, total OC levels were inversely associated with body
mass index. However, total OC levels were gender-depen-
dent, with significantly lower OC levels in males with
T1DM than in male controls [45]. This result is consistent
with a meta-analysis, revealing that total OC levels were
found to be reduced in T1DM patients [88]. Moreover, in
these meta-analysis, Starup-Linde et al. realized that CTX
levels were also significantly decreased in T1DM patients
and that bone biomarkers of bone formation and resorption
were not influenced by glucose itself but might be altered by
DM unknown factors [88].
Adiponectin is an adipocyte-specific protein and a major
regulator of bone mass and energy metabolism in the glucose
and lipid metabolism, and it circulates in human plasma at
high levels [5, 41, 66]. Adiponectin enhances insulin sensitiv-
ity by stimulating fatty acid oxidation, decreases plasma tri-
glycerides, and improves glucose metabolism [65, 89, 90].
The degree of visceral adiposity has revealed to be inversely
associated to adiponectin levels, acting as a negative predictor
of adiponectin. In Japanese T2DMmale patients, hypoadipo-
nectinemia was related with visceral fat accumulation rather
than subcutaneous fat [91]. Adiponectin levels are lower in
obese than in thin individuals and a reduction in adiponectin
expression is associated with insulin resistance. Concentra-
tions of plasma adiponectin are negatively associated with
glucose, insulin, triglyceride levels, and body mass index.
Accordingly, adiponectin levels are positively related with
insulin sensitivity both in healthy and diabetic individuals
and insulin-stimulated glucose disposal [5, 90, 92]. Reduced
expression of adiponectin has been associated with some
degree of insulin resistance, indicating a role for hypoadipo-
nectinemia in relation to insulin resistance [4, 89, 90]. Thus,
in several insulin-resistant states, such as obesity, T2DM and
in patients with coronary artery disease adiponectin plasma
levels are reported to be reduced. Yet increased plasma adi-
ponectin levels are reported to be related with T1DM and
anorexia nervosa and higher insulin sensitivity. A decrease
in plasma glucose levels and an increase in insulin sensitivity
with adiponectin administration have been verified [5, 27,
92]. Moreover, adiponectin influences the development of
insulin resistance and T2DM. The activity of adiponectin is
associated with leptin, resistin, steroid and thyroid hor-
mones, and glucocorticoids, among others [4, 27, 65].
3.4. Adiponectin and Regulations. It was observed that circu-
latory levels of adiponectin were negative predictors of BMD
and have negative effects on trabecular bone, whereas leptin
was found to be a positive predictor [5]. In mice lacking
Esp, the expression and circulating levels of leptin, an
insulin-sensitizing hormone, was not affected, whereas adi-
ponectin was increased [31]. Adiponectin has the skill to
stimulate insulin sensitivity and has antiatherogenic and
anti-inflammatory properties; thus, adiponectin is essential
for physiological and pathophysiological studies with the
aim of potential therapeutic applications [65, 69, 83, 92], par-
ticularly in states associated with low plasma adiponectin
levels. It may prevent also age-related bone loss by decreasing
the sympathetic nervous system as a regulator of bone mass
accrual [7, 66].
Adiponectin is identified for its insulin-sensitizing ability
in animals fed a high fat diet. However, adiponectin absence
in animals fed with a normal diet does not seem to clearly
alter insulin sensitivity, suggesting that adiponectin may
affect other physiological pathways than energy metabolism
[66]. However, adiponectin is identified for its insulin-
sensitizing ability in animals fed a high fat diet. This hor-
mone can affect bone tissue, since during evolution adipo-
nectin, as leptin, appear with bone and osteocalcin, may
stimulate adipose tissue to secrete this hormone [66].
Several studies suggest that adiponectin regulates and
applies two opposite mechanisms on bone mass formation.
Also, it partly antagonizes leptin regulation of the sympa-
thetic nervous system, inhibiting the activity of the sympa-
thetic tone. By acting centrally, adiponectin opposes several
functions of leptin. Its dual regulation occurs by decreasing
FoxO1 activity [66]. Adiponectin acts directly in osteoblasts,
by unknown signaling pathways, obstructing their prolifera-
tion, and enhances their apoptosis, through a PI3 kinase-
FoxO1-dependent process, decreasing both bone mass and
circulating osteocalcin levels. Adiponectin decreases FoxO1
activity in a PI3 kinase-dependent way in osteoblasts, accom-
plishing its roles, independently of its known receptors and
signaling pathways [53, 66]. However, adiponectin affects
bone mass accrual through a second mode of action, decreas-
ing the activity of the sympathetic nervous system. Thus,
adiponectin signals the neurons of the locus coeruleus, part
of the brainstem, through FoxO1, to reduce the activity of
the sympathetic tone, thereby increasing bone mass and
decreasing energy expenditure. Hence, adiponectin signals
by decreasing FoxO1 activity in osteoblasts and neurons. It
appears that the adipocyte is a rare, if not a unique, example
of an endocrine cell secreting two hormones with opposite
effects on the same physiological mechanisms. Therefore,
adipocytes seem to be of great importance in the control of
bone mass accrual [50, 53, 66].
4. Bone, Energy Homeostasis, and Glucose
Metabolism
Osteocalcin receptor GPRC6A is expressed in different tis-
sues including the liver, skeletal muscle, brain, testis, bone,
and pancreatic β-cells [20, 93–96]. Since the biological
action of osteocalcin in the brain does not rely on GPRC6A,
osteocalcin might have other undescribed physiological
functions [7, 28]. Glucose metabolism can be regulated by
5Journal of Diabetes Research
undercarboxylated osteocalcin directly, throughout the recep-
tor GPRC6A, increasing pancreatic β-cells proliferation and
enhancing insulin synthesis and secretion [7, 10, 23, 51].
Osteocalcin enhances energy expenditure and insulin sensi-
tivity via other mechanisms. Osteocalcin increases adiponec-
tin expression in white fat and reduces lipid accumulation
and inflammation in steatotic liver, and these mechanisms
may distress insulin sensitivity [19, 21, 24]. Furthermore,
osteocalcin controls the expression of genes implicated in
energy expenditure in brown adipose tissue [19, 24, 25]
and skeletal muscle. It also increases mitochondrial bio-
genesis in the muscle, stimulating energy consumption
[19, 24, 31, 51].
The outcome that energy metabolism affects bone turn-
over suggested that an endocrine feed-forward loop should
exist [24, 27, 31, 45]. The existence of a reciprocal regulation
between bone and energy metabolisms is supported by a
growing number of evidence [7, 28]. Bone remodeling occurs
continuously and simultaneously in several skeleton areas of
the body, and this physiological function is highly dependent
on the energetic status of the organism, requiring large
energy consumption. Therefore, bone and energy metabo-
lisms are unavoidably linked, and a coordinated endocrine
regulation of bone and energy metabolism must exist, where
hormones have been implicated in the control of bone
remodeling [5, 24, 27, 33]. As a result, impairments in glu-
cose metabolism may distress the skeleton [5, 27, 43].
4.1. Bone and Insulin Signaling. Insulin signaling in osteo-
blasts might regulate whole body glucose homeostasis by
controlling osteocalcin activation. Hence, osteocalcin bio-
availability is increased by insulin signaling in osteoblasts
through stimulating bone resorption [16, 24, 42]. Mice lack-
ing insulin receptor (InsR) showed compromised insulin
sensitivity, insulin secretion, and glucose tolerance. Also,
these mice accumulate more fat than those in control
groups and revealed reduced energy expenditure and serum
levels of undercarboxylated osteocalcin [16, 24, 42, 44].
With respect to the former, correlation concerning fat and
bone is assorted in overall energy metabolism due to its
paracrine and endocrine functions, and osteocalcin, leptin,
and adiponectin are essential hormones in bone remodeling
process [5, 24, 27]. However, bone and pancreas are also
related in the control of energy metabolism and bone mass,
being insulin and undercarboxylated osteocalcin the biolog-
ical molecules involved in this endocrine path. Osteocalcin
regulates energy metabolism, in part, by enhancing insulin
secretion by pancreatic β-cells [16, 31, 42, 66]. In a feed-
back loop, insulin signals back in osteoblasts to increase
osteocalcin activity and thus insulin secretion [16, 42, 66].
Osteocalcin also signals in adipocytes, where it favors the
synthesis of adiponectin, improving glucose metabolism by
stimulating the adipocyte sensitivity to insulin and insulin
secretion [5, 31, 66].
Recent studies suggest that bone may as well control
insulin sensitivity given that the deletion of insulin recep-
tor in osteoblasts conducts to insulin resistance and obesity.
Osteoblasts express the insulin receptor and when activated
by insulin promotes osteoclast resorption, providing
osteocalcin undercarboxylation [5, 16, 20, 42]. Since the dele-
tion of the insulin receptor in muscle was not associated
before with alterations in blood glucose, serum insulin, and
glucose tolerance, bone may be the tissue involved in insulin
and glucose regulation circuit [20, 26, 42]. The metabolic dis-
orders associated with the deletion of the insulin receptor are
rectified by osteocalcin administration. Besides, mice lacking
insulin receptor in the osteoblast demonstrated an osteope-
nic phenotype. These observations propose that insulin and
undercarboxylated osteocalcin are the molecules implicated
in bone and pancreas interconnection for the control of
energy metabolism and bone mass [5, 10, 19, 28].
4.2. Osteokines and Glucose Metabolism. Another study
found that bone has a crucial assignment in the control of
energy metabolism through osteocalcin and osteoblasts.
The findings suggest that, underneath the control of glucose
metabolism, a bone-derived factor other than osteocalcin
must be implicated [29]. Actually, there are already studies
discussing the role of NPY coming from the bone tissue or
of sclerostin as other osteokine which could also play a
role in glucose metabolism, needing further investigation
[97–99]. The study conducted by Yoshikawa et al. [29] issued
that similar to the phenotype observed in osteocalcin-
deficient mice, partial ablation of osteoblasts in adult mice
fallouts in metabolic abnormalities such as hypoinsulinemia,
hyperglycemia, glucose intolerance, and decreased insulin
sensitivity, mainly reversed by undercarboxylated osteocal-
cin injection. However, osteoblast ablation also decreased
gonadal fat and increased energy expenditure, unlike osteo-
calcin suppression [29]. Additionally, Sato et al. [100]
recently revealed that osteocyte-null mice shows adipose tis-
sue atrophy and decreased total osteocalcin, suggesting the
implication of another osteocyte-derived factor in these phe-
notypes. Osteocytes are mature bone cells derived from oste-
oblasts that are actively involved in local bone turnover,
through mechanosensory mechanisms. Together, these
observations suggest that additional osteoblast or osteocyte-
derived factors might be implicated in the endocrine regula-
tion of glucose metabolism by bone [100].
Regarding the effect of circulating levels of insulin and
osteocalcin on bone turnover, published studies showed that
biomarkers of bone resorption positively links with insulin
sensitivity/secretion and serum levels of undercarboxylated
osteocalcin [15, 33, 101]. Moreover, Lacombe et al. [33]
demonstrated that glucose intolerance negatively links with
the serum levels of undercarboxylated osteocalcin, support-
ing the idea that the activation of osteocalcin in vivo is neces-
sary to a suitable bone. The authors suggested that proper
bone resorption by osteoclasts is required for the partial
decarboxylation and activation of osteocalcin in vivo and
determinant for glucose metabolism in mice. These authors
realized that an increased number of osteoclasts induced
augmented serum levels of undercarboxylated osteocalcin
and improved glucose tolerance [33]. Furthermore, phar-
macological inhibition of bone resorption or osteoclast abla-
tion seems to be associated with reduced serum levels of
undercarboxylated osteocalcin and compromised glucose
tolerance [16, 33, 42].
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4.3. Osteoblast-Specific FoxO1, Opg Expression, and Glucose
Metabolism. The Forkhead transcription factor FoxO1,
through its expression in osteoblasts and due to its ability
to suppress the activity of osteocalcin by stimulating osteo-
calcin carboxylation, reduces β-cell proliferation and insulin
secretion [46, 52, 53] and decreases insulin sensitivity in
insulin-target tissues such as adipose tissue, the liver, and
the muscle, increasing blood glucose levels and hence affect-
ing energy expenditure and glucose metabolism. Interest-
ingly, in a feedback mechanism of regulation, insulin
signaling suppresses FoxO1 activity in osteoblasts, stimulat-
ing the activity of osteocalcin [16, 46, 52, 53]. In a whole-
organism approach to physiology, FoxO1 can regulate glu-
cose homeostasis by its linkage among skeleton, pancreas,
and insulin target organs through regulation of insulin
actions and osteocalcin activity [29, 31, 42, 53]. An in vitro
study carried out by Ferron et al. revealed that FoxO1 con-
trols Opg expression in osteoblasts and suppression of Opg
expression by insulin signaling, inducing FoxO1 phosphory-
lation which results in its nuclear export [16, 24]. Accord-
ingly, in an experimental study in mice lacking FoxO1, only
in osteoblasts, mice displayed a reduced level of Opg in bone
and an increased number of osteoclasts, amplified β-cell pro-
liferation, insulin secretion, and insulin sensitivity [52]. This
study, developed by Rached et al. [52], also reported that
serum levels and expression of adiponectin were amplified.
Moreover, the expression of osteocalcin increased 50%,
the circulatory levels of osteocalcin increased 30%, and the
Esp expression was reduced 75%. However, the removal of
a single osteocalcin allele from mice lacking FoxO1 resulted
in a complete reversal of the metabolic abnormalities of the
previous data [52]. Therefore, these findings support the
hypothesis of glucose homeostasis regulation by osteoblasts
[5, 52, 102].
Another study conducted by Rached et al. [102] demon-
strated that FoxO1 is essential for proliferation and redox
balance in osteoblasts, controlling bone formation. Osteopo-
rosis is associated with reduced number of osteoblasts and
increased levels of oxidative stress in these cells and the
FoxO1 assigns stress resistance. FoxO1 regulation of osteo-
blast proliferation occurs because of its interaction with
ATF4 [102]. In mice lacking FoxO1 in osteoblasts, reducing
oxidative stress levels or increasing protein intake regularizes
bone formation and bone mass. These data find FoxO1 as an
essential regulator of osteoblast physiology and a connection
between oxidative stress and the regulation of bone remodel-
ing [102]. The transcription factor ATF4 plays a role in glu-
cose metabolism and insulin sensitivity by acting through
osteoblasts [46, 47]. ATF4 is necessary to directly induce
Esp expression in osteoblasts [24, 47, 103]. Experimental
studies with mice with ATF4 ablation in osteoblasts or in
all tissues revealed improved glucose tolerance, insulin secre-
tion, and insulin sensitivity in the liver, fat, and muscle, like-
wise with mice lacking FoxO1 [24, 47, 104]. It was suggested
that ATF4 forms dimers with other transcription factors,
including FoxO1 in osteoblasts. Kode et al. [46] proposed
that ATF4 and FoxO1 synergistically combined in this func-
tional complex induce Esp expression in osteoblasts, by
directly binding to the Esp promoter and subsequently,
promote glucose intolerance and compromise insulin pro-
duction and sensitivity. These results establish that FoxO1
and ATF4 in bone regulate glucose homeostasis.
Furthermore, osteoclast gain-and-loss function models
suggest that osteoclasts take part in bone’s endocrine role
and that controlling the number of osteoclasts or its activity
affect glucose metabolism. The lack of Opg in mice results
in an intensified bone resorption leads to an amplified num-
ber of active osteoclasts, increased undercarboxylated osteo-
calcin, and glucose tolerance. However, there is a decrease
in undercarboxylated osteocalcin and glucose tolerance in
the absence of osteoclasts in mice. In this last animal model,
a decrease in β-cell mass and insulin secretion is also
observed [21, 24, 33]. These findings suggest that variations
in osteoclastic activity modulate undercarboxylated osteocal-
cin and indicate that osteoclasts control glucose metabolism,
leastwise for endorsing osteocalcin decarboxylation and acti-
vation in vivo. Although it should not be rejected that bone
resorption might regulate glucose metabolism independently
of osteocalcin.
Further investigation in physiological functions may lead
to the discovery of other tissues’ interconnections, enabling
an enhanced understanding of the pathogenesis of these dis-
eases and the development of conceivable therapies.
5. Conclusions
Besides its predictable functions of body support and loco-
motion, bone is now considered to play an important role
in a whole-organism approach to physiology. In fact, bone
has proven to be an endocrine organ since it is metabolically
active by secreting osteocalcin, a bone-specific protein associ-
ated to the energy and glucose homeostasis.
Bone has the ability to constantly renew itself, represent-
ing a key function on skeleton by repairing macro- and
microinjuries. Published results indicate that bone remodel-
ing and appetite might be regulated by the same hormones
since low body mass index enhances bone loss and usually
contributes to osteoporosis. Findings also suggest that bone
resorption is determinant for glucose metabolism. An
increasing number of osteoclasts are related with increased
bone resorption, increased serum levels of undercarboxylated
osteocalcin, and improved glucose tolerance. Additionally, a
recent study showed new evidence of osteoblast-mediated
glucose homoeostasis, proposing that osteoblasts have a cru-
cial role in FoxO1-mediated actions on insulin and therefore
in control of glucose homoeostasis by enhanced β-cell prolif-
eration, insulin secretion, and insulin sensitivity.
Moreover, the interaction between adipose tissue and
bone is significant. Adipokines such as leptin and adiponec-
tin, secreted by adipocytes, control energy homeostasis, but
also have complex actions on bone cells. Leptin, a molecule
involved in appetite regulation and energy metabolism is
considered to provide the brain feedback concerning energy
storage. Actually, leptin controls osteoblast function system
and osteoblasts control energy metabolism through osteo-
calcin. Actually, leptin affects insulin secretion by decreas-
ing osteocalcin bioactivity. A common regulatory link
between bone remodeling and energy metabolism has been
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established. Adiponectin appears to be a major regulator of
bone mass and energy metabolism. In addition to its capac-
ity to decrease activity of the sympathetic nervous system,
thereby increasing bone mass and decreasing energy expen-
diture, adiponectin also acts directly on osteoblasts, inhibit-
ing its proliferation and favoring its apoptosis. Hence,
adiponectin regulates and applies two opposite mechanisms
on bone mass accrual and partly antagonizes leptin regula-
tion of the sympathetic tone. These results revealed that
besides a cross regulation between the skeleton and energy
metabolism, there is also a very tight functional relationship
between fat cells and osteoblasts. Summing up, osteocalcin
and insulin rise each other’s activities or secretion in a feed-
forward loop. Insulin acts positively on osteocalcin produc-
tion and activation, which increases β-cell proliferation,
insulin secretion, and adiponectin production on adipose tis-
sue, enhancing peripheral insulin sensitivity, whereas other
hormones, including leptin and glucocorticoids, negatively
regulate osteocalcin activity by suppressing osteoblast func-
tion, osteocalcin secretion, and energy expenditure. There-
fore, osteocalcin has been associated to the regulation of
glucose and energy homeostasis.
Novel insights have emerged a new perspective in
which skeleton plays a key role in the integrative approach
to physiology associated with energy homeostasis and glu-
cose metabolism. Future research on bone function shall
clarify if it has potential therapeutic implications in diabe-
tes, obesity, metabolic syndrome, and identify new targets
for treatment.
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